Title:
METHOD FOR EXAMINING AT LEAST ONE RISK SELECTED FROM GROUP CONSISTING OF SYMPTOM EXPRESSION RISK, AGGRAVATION RISK, COMPLICATION ONSET RISK, AND LONG-TERM HOSPITALIZATION RISK WHEN AFFLICTED WITH COVID-19, EXAMINATION DEVICE, AND EXAMINATION PROGRAM
Document Type and Number:
WIPO Patent Application WO/2023/181572
Kind Code:
A1
Abstract:
An examination method according to the present embodiment measures at least one type of data among gene composition data for intestinal microbiota, blood metabolite data, and bacteria composition data for intestinal microbiota in a biological sample collected from a subject. At least one of the gene composition data for intestinal microbiota and the blood metabolite data is used to examine at least one risk selected from the group consisting of the symptom expression risk, the aggravation risk, the complication onset risk, and the long-term hospitalization risk when afflicted with COVID-19, and the bacteria composition data for intestinal microbiota is used to examine at least one risk selected from the group consisting of the symptom expression risk, the complication onset risk, and the long-term hospitalization risk when afflicted with COVID-19.
Inventors:
NAGATA NAOYOSHI (JP)
ISHIKANE MASAHIRO (JP)
IWAMOTO NORIKO (JP)
TAKEUCHI TADASHI (JP)
OHNO HIROSHI (JP)
SUDA WATARU (JP)
NAKANISHI YUMIKO (JP)
MASUOKA HIROAKI (JP)
AOKI RYO (JP)
NISHIJIMA TOMOHIKO (JP)
INOOKA HIROSHI (JP)
ISHIKANE MASAHIRO (JP)
IWAMOTO NORIKO (JP)
TAKEUCHI TADASHI (JP)
OHNO HIROSHI (JP)
SUDA WATARU (JP)
NAKANISHI YUMIKO (JP)
MASUOKA HIROAKI (JP)
AOKI RYO (JP)
NISHIJIMA TOMOHIKO (JP)
INOOKA HIROSHI (JP)
Application Number:
PCT/JP2022/048200
Publication Date:
September 28, 2023
Filing Date:
December 27, 2022
Export Citation:
Assignee:
EZAKI GLICO CO (JP)
UNIV TOKYO MEDICAL (JP)
NAT CENTER FOR GLOBAL HEALTH AND MEDICINE (JP)
RIKEN (JP)
UNIV TOKYO MEDICAL (JP)
NAT CENTER FOR GLOBAL HEALTH AND MEDICINE (JP)
RIKEN (JP)
International Classes:
C12Q1/04; C12M1/00; C12Q1/6851; C12Q1/6869; G01N33/50; C12N15/09
Other References:
LIU YIJUN, ZHANG HONGYANG, TANG XIAOJUN, JIANG XUEJUN, YAN XIAOJUAN, LIU XIZHAO, GONG JIANG, MEW KENLEY, SUN HAO, CHEN XIUFENG, ZO: "Distinct Metagenomic Signatures in the SARS-CoV-2 Infection", FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, vol. 11, XP093094880, DOI: 10.3389/fcimb.2021.706970
LI SIJIA, YANG SIYUAN, ZHOU YUZHENG, DISOMA CYROLLAH, DONG ZIJUN, DU ASHUAI, ZHANG YONGXING, CHEN YONG, HUANG WEILIANG, CHEN JUNRU: "Microbiome Profiling Using Shotgun Metagenomic Sequencing Identified Unique Microorganisms in COVID-19 Patients With Altered Gut Microbiota", FRONTIERS IN MICROBIOLOGY, vol. 12, XP093094881, DOI: 10.3389/fmicb.2021.712081
BUYUKOZKAN MUSTAFA, ALVAREZ-MULETT SERGIO, RACANELLI ALEXANDRA C., SCHMIDT FRANK, BATRA RICHA, HOFFMAN KATHERINE L., SARWATH HINA,: "Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19", MEDRXIV, 11 February 2022 (2022-02-11), XP093094885, Retrieved from the Internet [retrieved on 20231025], DOI: 10.1101/2021.07.19.21260776
ROBERTS, IVAYLA ET AL.: "Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome", METABOLOMICS, vol. 18, 2021, pages 6, XP037647119, DOI: 10.1007/sll306-021-01859-3>
SINDELAR MIRIAM, STANCLIFFE ETHAN, SCHWAIGER-HABER MICHAELA, ANBUKUMAR DHANALAKSHMI S., ADKINS-TRAVIS KAYLA, GOSS CHARLES W., O’HA: "Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity", CELL REPORTS MEDICINE, vol. 2, no. 8, 1 August 2021 (2021-08-01), pages 100369, XP093094887, ISSN: 2666-3791, DOI: 10.1016/j.xcrm.2021.100369
SCHULT DAVID, REITMEIER SANDRA, KOYUMDZHIEVA PLAMENA, LAHMER TOBIAS, MIDDELHOFF MORITZ, ERBER JOHANNA, SCHNEIDER JOCHEN, KAGER JUL: "Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19", GUT MICROBES, LANDES BIOSCIENCE, UNITED STATES, vol. 14, no. 1, 31 December 2022 (2022-12-31), United States , XP093094888, ISSN: 1949-0976, DOI: 10.1080/19490976.2022.2031840
LI SIJIA, YANG SIYUAN, ZHOU YUZHENG, DISOMA CYROLLAH, DONG ZIJUN, DU ASHUAI, ZHANG YONGXING, CHEN YONG, HUANG WEILIANG, CHEN JUNRU: "Microbiome Profiling Using Shotgun Metagenomic Sequencing Identified Unique Microorganisms in COVID-19 Patients With Altered Gut Microbiota", FRONTIERS IN MICROBIOLOGY, vol. 12, XP093094881, DOI: 10.3389/fmicb.2021.712081
BUYUKOZKAN MUSTAFA, ALVAREZ-MULETT SERGIO, RACANELLI ALEXANDRA C., SCHMIDT FRANK, BATRA RICHA, HOFFMAN KATHERINE L., SARWATH HINA,: "Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19", MEDRXIV, 11 February 2022 (2022-02-11), XP093094885, Retrieved from the Internet
ROBERTS, IVAYLA ET AL.: "Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome", METABOLOMICS, vol. 18, 2021, pages 6, XP037647119, DOI: 10.1007/sll306-021-01859-3>
SINDELAR MIRIAM, STANCLIFFE ETHAN, SCHWAIGER-HABER MICHAELA, ANBUKUMAR DHANALAKSHMI S., ADKINS-TRAVIS KAYLA, GOSS CHARLES W., O’HA: "Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity", CELL REPORTS MEDICINE, vol. 2, no. 8, 1 August 2021 (2021-08-01), pages 100369, XP093094887, ISSN: 2666-3791, DOI: 10.1016/j.xcrm.2021.100369
SCHULT DAVID, REITMEIER SANDRA, KOYUMDZHIEVA PLAMENA, LAHMER TOBIAS, MIDDELHOFF MORITZ, ERBER JOHANNA, SCHNEIDER JOCHEN, KAGER JUL: "Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19", GUT MICROBES, LANDES BIOSCIENCE, UNITED STATES, vol. 14, no. 1, 31 December 2022 (2022-12-31), United States , XP093094888, ISSN: 1949-0976, DOI: 10.1080/19490976.2022.2031840
Attorney, Agent or Firm:
TACHIBANA, Kenji (JP)
Download PDF:
Previous Patent: DATA OUTPUT METHOD, PROGRAM, DATA OUTPUT DEVICE, AND ELECTRONIC MUSICAL INSTRUMENT
Next Patent: INPUT DEVICE
Next Patent: INPUT DEVICE